INGALLS KERRY D. (Chief Operating Officer) purchased 5.8% of their position (3K shares) of POSEIDA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $11.9K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 3/18/2022ACC: 0001209191-22-020153
Officer· Chief Operating Officer
Since Jul 2020
+3K
Net shares
Net buyer
$11.9K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
3K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+3K
Price / share
$3.98
Trade value
$11.94K
% of position
5.8%
3/16/2022
52K→55K
Total
Net shares
+3K
Net value
$11.94K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/16/2022 | P · Purchase | +3K | $3.98 | $11.94K | 5.8% | 52K | 55K |
| Total | +3K | $11.94K | ||||||
Derivative Transactions0
No derivative transactions reported